title: RNA-Seq of C2C12 cell line
design: Differentiated C2C12 myotubes were divided into three groups, control, dexamethasone (DEX)-induced atrophic myotubes and tFNAs treatment after DEX-induced groups. For in vitro model of sarcopenia50M dexamethasone (DEX, Solarbio, Beijing, China)-induced myotube atrophy was employed. After C2C12 myotubes were differentiated, the medium was replaced by differentiation medium with 50M DEX and cultivated for 24h. For tFNAs group, medium was replaced with differentiation medium with 25nM tFNAs for 24h after establishment of DEX-induced myotube atrophy.